Cargando…
A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry
BACKGROUND: Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794868/ https://www.ncbi.nlm.nih.gov/pubmed/31615560 http://dx.doi.org/10.1186/s13019-019-1010-z |
_version_ | 1783459382568157184 |
---|---|
author | Caliskan, Etem Sandner, Sigrid Misfeld, Martin Aramendi, Jose Salzberg, Sacha P. Choi, Yeong-Hoon Satishchandran, Vilas Iyer, Geeta Perrault, Louis P. Böning, Andreas Emmert, Maximilian Y. |
author_facet | Caliskan, Etem Sandner, Sigrid Misfeld, Martin Aramendi, Jose Salzberg, Sacha P. Choi, Yeong-Hoon Satishchandran, Vilas Iyer, Geeta Perrault, Louis P. Böning, Andreas Emmert, Maximilian Y. |
author_sort | Caliskan, Etem |
collection | PubMed |
description | BACKGROUND: Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft registry will evaluate the long-term clinical outcomes of DuraGraft in patients undergoing CABG procedures. METHODS: This ongoing multicentre, prospective observational registry will enrol 3000 patients undergoing an isolated CABG procedure or a combined procedure (ie, CABG plus valve surgery or other surgery) with at least one saphenous vein grafts or one free arterial graft (ie, radial artery or mammary artery). If a patient is enrolled, all free grafts (SVG and arterial will be treated with DuraGraft. Data on baseline, clinical, and angiographic characteristics as well as procedural and clinical events will be collected. The primary outcome measure is the occurrence of a major adverse cardiac event (MACE; defined as death, non-fatal myocardial-infarction, or need for repeat-revascularisation). Secondary outcome measures are the occurrence of major adverse cardiac and cerebrovascular events (MACCE; defined as death, non-fatal myocardial-infarction, repeat-revascularisation, or stroke), patient-reported quality of life, and health-economic data. Patient assessments will be performed during hospitalisation, at 1-month, 1-year, and annually thereafter to 5 years post-CABG. Events will be adjudicated by an independent clinical events committee. This European, multi-institutional registry will provide detailed insights into clinical outcome associated with DuraGraft. DISCUSSION: This European, multi-institutional registry will provide detailed insights into clinical outcome associated with the use of DuraGraft. Beyond that, and given the comprehensive data sets comprising of patient, procedural, and graft parameters that are being collected, the registry will enable for multiple subgroup analyses targeting focus groups or specific clinical questions. These may include analysis of subpopulations such as patients with diabetes or multimorbid high-risk patients (patient level), evaluation of relevance of harvesting technique including endoscopic versus open conduit harvesting (procedural level), or particular graft-specific aspects (conduit level). TRIAL REGISTRATION: ClinicalTrials.gov NCT02922088. Registered October 3, 2016. ETHICS AND DISSEMINATION: The regional ethics committees have approved the registry. Results will be submitted for publication. |
format | Online Article Text |
id | pubmed-6794868 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-67948682019-10-21 A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry Caliskan, Etem Sandner, Sigrid Misfeld, Martin Aramendi, Jose Salzberg, Sacha P. Choi, Yeong-Hoon Satishchandran, Vilas Iyer, Geeta Perrault, Louis P. Böning, Andreas Emmert, Maximilian Y. J Cardiothorac Surg Study Protocol BACKGROUND: Vein graft disease (VGD) impairs graft patency rates and long-term outcomes after coronary artery bypass grafting (CABG). DuraGraft is a novel endothelial-damage inhibitor developed to efficiently protect the structural and functional integrity of the vascular endothelium. The DuraGraft registry will evaluate the long-term clinical outcomes of DuraGraft in patients undergoing CABG procedures. METHODS: This ongoing multicentre, prospective observational registry will enrol 3000 patients undergoing an isolated CABG procedure or a combined procedure (ie, CABG plus valve surgery or other surgery) with at least one saphenous vein grafts or one free arterial graft (ie, radial artery or mammary artery). If a patient is enrolled, all free grafts (SVG and arterial will be treated with DuraGraft. Data on baseline, clinical, and angiographic characteristics as well as procedural and clinical events will be collected. The primary outcome measure is the occurrence of a major adverse cardiac event (MACE; defined as death, non-fatal myocardial-infarction, or need for repeat-revascularisation). Secondary outcome measures are the occurrence of major adverse cardiac and cerebrovascular events (MACCE; defined as death, non-fatal myocardial-infarction, repeat-revascularisation, or stroke), patient-reported quality of life, and health-economic data. Patient assessments will be performed during hospitalisation, at 1-month, 1-year, and annually thereafter to 5 years post-CABG. Events will be adjudicated by an independent clinical events committee. This European, multi-institutional registry will provide detailed insights into clinical outcome associated with DuraGraft. DISCUSSION: This European, multi-institutional registry will provide detailed insights into clinical outcome associated with the use of DuraGraft. Beyond that, and given the comprehensive data sets comprising of patient, procedural, and graft parameters that are being collected, the registry will enable for multiple subgroup analyses targeting focus groups or specific clinical questions. These may include analysis of subpopulations such as patients with diabetes or multimorbid high-risk patients (patient level), evaluation of relevance of harvesting technique including endoscopic versus open conduit harvesting (procedural level), or particular graft-specific aspects (conduit level). TRIAL REGISTRATION: ClinicalTrials.gov NCT02922088. Registered October 3, 2016. ETHICS AND DISSEMINATION: The regional ethics committees have approved the registry. Results will be submitted for publication. BioMed Central 2019-10-15 /pmc/articles/PMC6794868/ /pubmed/31615560 http://dx.doi.org/10.1186/s13019-019-1010-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Study Protocol Caliskan, Etem Sandner, Sigrid Misfeld, Martin Aramendi, Jose Salzberg, Sacha P. Choi, Yeong-Hoon Satishchandran, Vilas Iyer, Geeta Perrault, Louis P. Böning, Andreas Emmert, Maximilian Y. A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title | A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title_full | A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title_fullStr | A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title_full_unstemmed | A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title_short | A novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the European, multicentre, prospective, observational DuraGraft registry |
title_sort | novel endothelial damage inhibitor for the treatment of vascular conduits in coronary artery bypass grafting: protocol and rationale for the european, multicentre, prospective, observational duragraft registry |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6794868/ https://www.ncbi.nlm.nih.gov/pubmed/31615560 http://dx.doi.org/10.1186/s13019-019-1010-z |
work_keys_str_mv | AT caliskanetem anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT sandnersigrid anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT misfeldmartin anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT aramendijose anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT salzbergsachap anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT choiyeonghoon anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT satishchandranvilas anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT iyergeeta anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT perraultlouisp anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT boningandreas anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT emmertmaximiliany anovelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT caliskanetem novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT sandnersigrid novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT misfeldmartin novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT aramendijose novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT salzbergsachap novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT choiyeonghoon novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT satishchandranvilas novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT iyergeeta novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT perraultlouisp novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT boningandreas novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry AT emmertmaximiliany novelendothelialdamageinhibitorforthetreatmentofvascularconduitsincoronaryarterybypassgraftingprotocolandrationalefortheeuropeanmulticentreprospectiveobservationalduragraftregistry |